Magnetic resonance imaging of tumor oxygenation and metabolic profile

Abstract The tumor microenvironment is distinct from normal tissue as a result of abnormal vascular network characterized by hypoxia, low pH, high interstitial fluid pressure and elevated glycolytic activity. This poses a barrier to treatments including radiation therapy and chemotherapy. Imaging methods which can characterize such features non-invasively and repeatedly will be of significant value in planning treatment as well as monitoring response to treatment. The three techniques based on magnetic resonance imaging (MRI) are reviewed here. Tumor pO2 can be measured by two MRI methods requiring an exogenous contrast agent: electron paramagnetic resonance imaging (EPRI) and Overhauser magnetic resonance imaging (OMRI). Tumor metabolic profile can be assessed by a third method, hyperpolarized metabolic MR, based on injection of hyperpolarized biological molecules labeled with 13C or 15N and MR spectroscopic imaging. Imaging pO2 in tumors is now a robust pre-clinical imaging modality with potential for implementation clinically. Pre-clinical studies and an initial clinical study with hyperpolarized metabolic MR have been successful and suggest that the method may be part of image-guided radiotherapy to select patients for tailored individual treatment regimens.

[1]  James B. Mitchell,et al.  Imaging cycling tumor hypoxia. , 2010, Cancer research.

[2]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[3]  J. Petersen,et al.  Imaging hypoxia to improve radiotherapy outcome , 2012, Nature Reviews Clinical Oncology.

[4]  James L Tatum,et al.  Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy , 2006, International journal of radiation biology.

[5]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[6]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[7]  James B. Mitchell,et al.  Overhauser enhanced magnetic resonance imaging for tumor oximetry: Coregistration of tumor anatomy and tissue oxygen concentration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Sarah E Bohndiek,et al.  Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors , 2009, Proceedings of the National Academy of Sciences.

[9]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[10]  Jan Wolber,et al.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy , 2007, Nature Medicine.

[11]  J. Overgaard,et al.  Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers. , 1996, Seminars in radiation oncology.

[12]  Albert P. Chen,et al.  Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. , 2008, Cancer research.

[13]  C. Grau,et al.  Biology-guided adaptive radiation therapy – presence or future? , 2010, Acta oncologica.

[14]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[15]  Shingo Matsumoto,et al.  EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3‐bromopyruvate , 2013, Magnetic resonance in medicine.

[16]  J. Ardenkjær-Larsen,et al.  Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Bastholt,et al.  A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  M. Welch,et al.  PET imaging of hypoxia. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[19]  R. Gillies,et al.  Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? , 2007, Journal of bioenergetics and biomembranes.

[20]  D. Chaplin,et al.  Intermittent blood flow in a murine tumor: radiobiological effects. , 1987, Cancer research.

[21]  J S Petersson,et al.  EPR and DNP properties of certain novel single electron contrast agents intended for oximetric imaging. , 1998, Journal of magnetic resonance.

[22]  Jan H. Ardenkjær-Larsen,et al.  Molecular imaging with endogenous substances , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Grau,et al.  Image-guided adaptive radiotherapy – integration of biology and technology to improve clinical outcome , 2008, Acta oncologica.

[24]  Shingo Matsumoto,et al.  Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. , 2008, The Journal of clinical investigation.

[25]  J. Overgaard.  Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.